Verzenio (Abemaciclib)

Verzenio is a medicine for a common type of breast cancer that grows in response to hormones. It is a pill taken twice a day, usually along with a hormone-blocking medicine. It works by blocking proteins that cancer cells need to divide and grow.

Brand names:Verzenio
Medication

What people taking Verzenio (Abemaciclib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Verzenio (Abemaciclib) for Breast Cancer?

NameHow it went

About Verzenio (Abemaciclib)

What It's For

Abemaciclib, sold as Verzenio, is a targeted cancer pill for the most common type of breast cancer: hormone receptor-positive, HER2-negative disease. Hormone receptor-positive (HR-positive) means the cancer cells use estrogen or progesterone to grow. HER2-negative means the cells do not carry extra amounts of a growth protein called HER2, so medicines aimed at HER2 do not apply. Verzenio is almost always paired with hormone therapy, which works on the same cancer from a different direction. In early breast cancer, Verzenio is added to hormone therapy (tamoxifen, or an aromatase inhibitor, a type of pill that lowers estrogen levels) after surgery. It is meant for adults whose cancer had reached the lymph nodes and who have a high chance of it coming back, and it is taken for up to two years. In advanced or metastatic breast cancer (cancer that has spread or cannot be removed with surgery), it is used with an aromatase inhibitor as a first hormone-based treatment, or with fulvestrant, an injected estrogen blocker, after the cancer has grown during earlier hormone therapy. It can also be paired with imlunestrant (Inluriyo), a newer estrogen-blocking pill, when the cancer has grown despite hormone therapy and a blood test finds a change in the estrogen receptor gene called an ESR1 mutation. For advanced cancer that has already progressed after both hormone therapy and chemotherapy, Verzenio can be used on its own.

How It Works

Cancer grows because its cells keep dividing. Before a cell can copy its DNA and split in two, it has to pass a checkpoint controlled in part by two enzymes, CDK4 and CDK6 (cyclin-dependent kinases 4 and 6). In HR-positive breast cancer cells, these enzymes help drive the steady division the tumor depends on. Abemaciclib blocks CDK4 and CDK6, holding cancer cells at that checkpoint so they stop dividing. In laboratory studies, cells held there for long enough stopped growing for good or died. Hormone therapy cuts off the estrogen signal that feeds the same growth, which is why the two are usually given together. Verzenio slows or stops the cancer rather than dissolving it outright, and the medicine also affects some healthy tissues, which shows up mainly as diarrhea and lower white blood cell counts.

Dosage & Administration

Verzenio is a tablet taken twice a day, at about the same times each day, with or without food. When it is combined with hormone therapy, the usual starting dose is 150 mg twice a day; when it is taken on its own, it is 200 mg twice a day. Tablets come in 50, 100, 150 and 200 mg strengths, so the care team can lower the dose in steps. Lowering or pausing the dose is a routine way to manage side effects such as diarrhea. People with severe liver impairment take it once a day instead. Swallow the tablets whole. Do not chew, crush or split them, and do not take a tablet that is broken or cracked. If a dose is missed, or if you vomit after taking it, skip that dose and take the next one at the usual time rather than doubling up. Women who have not been through menopause, and men, who take Verzenio with an aromatase inhibitor, fulvestrant or imlunestrant also receive a hormone-suppressing medicine called a GnRH agonist (gonadotropin-releasing hormone agonist). For early breast cancer, treatment lasts up to two years. For advanced cancer, it continues for as long as it keeps the cancer in check and side effects remain manageable.

Side Effects

Diarrhea is the side effect most people notice. It affects more than 8 in 10 people taking Verzenio, usually starts within the first week or so, and is most common in the first month. The plan is to act at the first loose stool: start an antidiarrheal medicine such as loperamide, drink more fluids, and let the care team know. Untreated, severe diarrhea can lead to dehydration and infection, and it is one of the most common reasons the dose is paused or lowered. Other common effects include tiredness, nausea, vomiting, belly pain, infections and low blood counts, both white cells (which fight infection) and red cells (which carry oxygen). Because low white cell counts make infections harder to fight, a fever, especially with other signs of infection, needs an immediate call to the care team. A few less common side effects are serious and worth catching early. Call the care team right away for a new or worsening cough or shortness of breath, which can signal inflammation of the lungs (pneumonitis); for signs of liver trouble, such as yellowing of the skin or eyes or pain in the upper right belly; or for pain or swelling in an arm or leg, which can mean a blood clot. Sudden chest pain or sudden trouble breathing can mean a clot has traveled to the lungs and needs medical care right away.

Interactions & Warnings

How much abemaciclib stays in the blood depends on a liver enzyme called CYP3A, so medicines that change that enzyme's activity change the dose a person effectively gets. Ketoconazole, an antifungal medicine, can raise abemaciclib levels many times over and should be avoided. Other medicines that slow CYP3A may call for a lower Verzenio dose, while medicines that speed it up can lower abemaciclib levels and weaken its effect, so alternatives are usually chosen. Grapefruit and grapefruit juice should be avoided during treatment. Tell the care team and pharmacist about every prescription, over-the-counter medicine, vitamin and herbal product, including St. John's wort, and check before starting anything new. Verzenio can harm a developing baby. People who could become pregnant should use effective birth control during treatment and for 3 weeks after the last dose, or longer if the hormone therapy taken with it requires that, and should tell the care team promptly about a known or suspected pregnancy. Breastfeeding is not recommended during treatment or for at least 3 weeks after the last dose. Verzenio may also reduce fertility in men. Verzenio can raise creatinine, a blood marker often used to judge kidney function, without actually harming the kidneys. The care team may use other tests to check kidney health so that this rise is not mistaken for kidney damage.

What to Expect

The first two months are the most closely watched. Blood counts and liver tests are checked before starting, every two weeks for the first two months, monthly for the next two months, and then as needed. The results, along with how diarrhea and tiredness are going, guide whether the dose is paused or lowered. Diarrhea usually eases once the antidiarrheal routine and any dose change are in place. In early breast cancer, Verzenio does not produce a change a person can feel. Its purpose is to lower the chance of the cancer returning. In the main trial of people with high-risk, lymph node-positive disease, 85.5% of those taking Verzenio with hormone therapy were free of invasive cancer four years after starting, compared with 78.6% of those taking hormone therapy alone. Verzenio stops after two years, while hormone therapy carries on; in that trial it continued for at least five years in total. In advanced breast cancer, the goal is to keep the cancer under control for as long as possible. In the main trial of first treatment for advanced disease, the median time before the cancer grew (the point at which half of people had progressed) was about 28 months with Verzenio plus an aromatase inhibitor, compared with about 15 months with the aromatase inhibitor alone. Scans show whether the cancer is responding, and treatment continues until the cancer grows or side effects become too hard to manage. How well it works varies widely from person to person.

Questions to Ask Your Doctor

  1. 1.Why is Verzenio a good fit for my type and stage of breast cancer, and how does it compare with other options, including other CDK4/6 inhibitors?
  2. 2.How much is it likely to lower my own risk of the cancer coming back, or how long might it keep my cancer under control?
  3. 3.What should I keep at home for diarrhea, and at what point should I call you about it?
  4. 4.How often will I need blood tests, and what results would lead us to pause or lower my dose?
  5. 5.Which of my current medicines, supplements or foods could interact with Verzenio?

Last reviewed • Oct 2026

Educational content, not medical advice.